Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTEGRATE IIb (regorafenib + nivolumab vs standard chemotherapy in refractory advanced gastro-oesophageal cancer)
2020-004617-12Phase 3Active
- Sponsor
- Australasian Gastro-Intestinal Trials Group
- Start
- Apr 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of regorafenib and nivolumab in esophagogastric junction cancer (2 arms), sponsored by Australasian Gastro-Intestinal Trials Group. Primary endpoint: Overall survival (overall study population). Started Apr 2023; status: active.
02
Drugs
regorafenibnivolumab
03
Conditions
esophagogastric junction cancer
Beyond the preview
Go deeper on 2020-004617-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004617-12.